Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Atrial fibrillation in cancer patients

Authors: Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F.

Company:
Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/I: 10.24022/1814-6910-2022-19-1-16-24

UDC: 616.12-008.313.2:616-006

Link: Clinical Physiology of Blood Circulaiton. 2022; 1 (19): 16-24

Quote as: Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F. Atrial fibrillation in cancer patients. Clinical Physiology of Circulation. 2022; 19 (1): 16–24 (in Russ.). DOI: 10.24022/1814-6910-2022-19-1-16-24

Received / Accepted:  21.10.2021 / 23.11.2021

Download
Full text:  

Abstract

Atrial fibrillation (AF) is the most common persistent arrhythmia and its occurrence is associated with a significant increase in hospitalizations and mortality from cardiovascular complications. Due to the lack of evidence in the prevention of ischemic stroke in patients with cancer and AF, it is usually performed in the same way as in patients who do not suffer from oncopathology, and randomized trials have not been conducted. However, this is a special category of patients, and it is important to pay attention to the stage of cancer, prognosis, and possible interaction with background chemotherapy. Patients with malignant neoplasms and AF require a multidisciplinary approach together with cardiologists and oncologists, careful planning of anticoagulant therapy and initiation of antiarrhythmic therapy. Further research will allow us to develop new tools for improving risk stratification in patients with AF and cancer, as well as determine the advantages in choosing optimal anticoagulant treatment strategies for both the prevention of thromboembolic complications and for stratifying the risk of major bleeding.

About Authors

  • Firdavsdzhon R. Akildzhonov, Postgraduate; ORCID
  • Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Head of Clinical and Diagnostic Department; ORCID
  • El’mira U. Asymbekova, Dr. Med. Sci., Leading Researcher; ORCID
  • El’vina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID

 If you found mistakes, select text and press Alt+A